Is Palantir a Good Stock to Buy?
Palantir Technologies (PLTR) stock soared to its highest level in…
Buy
73
ACCD Quote, Financials, Valuation and Earnings
Last price:
$7.01
Seasonality move
:
-16.57%
Day range:
$6.98 - $7.01
52-week range:
$3.08 - $10.68
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.23x
P/B ratio:
1.83x
Volume:
1.3M
Avg. volume:
1.3M
1-year change:
-28.1%
Market cap:
$572.6M
Revenue:
$414.3M
EPS (TTM):
-$2.25
Analysts' Opinion
-
Consensus RatingAccolade has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 11 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.03, Accolade has an estimated upside of 0.22% from its current price of $7.01.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $7.00 representing 100% downside risk from its current price of $7.01.
Fair Value
-
According to the consensus of 11 analysts, Accolade has 0.22% upside to fair value with a price target of $7.03 per share.
ACCD vs. S&P 500
-
Over the past 5 trading days, Accolade has underperformed the S&P 500 by -0.08% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Accolade does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Accolade has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Accolade reported revenues of $105.1M.
Earnings Growth
-
Accolade has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Accolade reported earnings per share of -$1.50.
Enterprise value:
556.5M
EV / Invested capital:
--
Price / LTM sales:
1.23x
EV / EBIT:
--
EV / Revenue:
1.25x
PEG ratio (5yr expected):
-0.09x
EV / Free cash flow:
-43.67x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$214.4M
Return On Assets:
-24.08%
Net Income Margin (TTM):
-40.36%
Return On Equity:
-43.94%
Return On Invested Capital:
-29.12%
Operating Margin:
-24.61%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-11-30 | 2023-11-30 | 2024-11-30 | 2023-11-30 | 2024-11-30 | |
| Income Statement | ||||||
| Revenue | $357.9M | $388.5M | $446.7M | $99.4M | $105.1M | |
| Gross Profit | $166.4M | $173.4M | $214.4M | $44.9M | $46.5M | |
| Operating Income | -$169.6M | -$137.7M | -$87.9M | -$31.7M | -$25.9M | |
| EBITDA | -$422.9M | -$92.3M | -$45.6M | -$20.3M | -$15.8M | |
| Diluted EPS | -$6.65 | -$1.65 | -$2.25 | -$0.28 | -$1.50 | |
| Period Ending | 2020-11-30 | 2021-11-30 | 2022-11-30 | 2023-11-30 | 2024-11-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $444.5M | $407.6M | $366.2M | $272.1M | $272.4M | |
| Total Assets | $467.5M | $1.3B | $913.8M | $785.5M | $647.5M | |
| Current Liabilities | $73.4M | $184.6M | $116.6M | $115.7M | $103.6M | |
| Total Liabilities | $79.2M | $474.7M | $427.8M | $350.8M | $334.5M | |
| Total Equity | $388.3M | $788.7M | $486M | $434.7M | $313M | |
| Total Debt | -- | $280.3M | $281.9M | $208.2M | $209.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-11-30 | 2023-11-30 | 2024-11-30 | 2023-11-30 | 2024-11-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$40.4M | -$24.7M | -$6.8M | $5.2M | -$9.7M | |
| Cash From Investing | -$5.3M | -$12.8M | -$43.6M | -$3.7M | $21.2M | |
| Cash From Financing | $5.4M | -$58.2M | $6.2M | -$63.7M | $1.1M | |
| Free Cash Flow | -$45.9M | -$37.5M | -$12.7M | $1.5M | -$10.6M | |
ACCD
Sector
Market Cap
$572.6M
$39.2M
Price % of 52-Week High
65.64%
45.93%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
-28.1%
-38.63%
Beta (5-Year)
--
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$6.99
200-day SMA
Buy
Level
$4.77
Bollinger Bands (100)
Buy
Level
3.42 - 6.86
Chaikin Money Flow
Sell
Level
-53.8M
20-day SMA
Buy
Level
$6.97
Relative Strength Index (RSI14)
Buy
Level
78.89
ADX Line
Buy
Level
75.84
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$6.78
MACD (12, 26)
Buy
Level
0.11
25-day Aroon Oscillator
Buy
Level
96
On Balance Volume
Sell
Level
-5.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.1553)
Sell
CA Score
(Annual)
Level (-0.6833)
Buy
Beneish M-Score
(Annual)
Level (-2.9355)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (2.5276)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.
Stock Forecast FAQ
In the current month, ACCD has received 0 Buy ratings 11 Hold ratings, and 0 Sell ratings. The ACCD average analyst price target in the past 3 months is $7.03.
-
Where Will Accolade Stock Be In 1 Year?
According to analysts, the consensus estimate is that Accolade share price will rise to $7.03 per share over the next 12 months.
-
What Do Analysts Say About Accolade?
Analysts are divided on their view about Accolade share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Accolade is a Sell and believe this share price will drop from its current level to $7.00.
-
What Is Accolade's Price Target?
The price target for Accolade over the next 1-year time period is forecast to be $7.03 according to 11 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 11 analysts rate the stock a Hold.
-
Is ACCD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Accolade is a Hold. 11 of 11 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of ACCD?
You can purchase shares of Accolade via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Accolade shares.
-
What Is The Accolade Share Price Today?
Accolade was last trading at $7.01 per share. This represents the most recent stock quote for Accolade. Yesterday, Accolade closed at $7.01 per share.
-
How To Buy Accolade Stock Online?
In order to purchase Accolade stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Sportradar Stock Going Up?
Sportradar (NASDAQ:SRAD) should be on your radar for a stock…
Is Roblox Stock a Buy, Sell or Hold?
Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
